U.S. markets close in 5 hours 58 minutes

AVROBIO, Inc. (AVRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.48-0.06 (-0.57%)
As of 10:02AM EST. Market open.

AVROBIO, Inc.

Building 300
Suite 201 One Kendall Square
Cambridge, MA 02139
United States
617 914 8420
http://www.avrobio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees123

Key Executives

NameTitlePayExercisedYear Born
Mr. Geoff MacKayCo- Founder, Pres, CEO & Director746.7kN/A1966
Mr. Erik Ostrowski M.B.A.CFO & Treasurer739.58kN/A1973
Mr. Steven N. Avruch J.D.Chief Legal Officer & Sec.441.68kN/A1961
Mr. Jeffrey Medin Ph.D.Scientific FounderN/AN/AN/A
Mr. Matthew ArnoldHead of OperationsN/AN/AN/A
Mr. Kim Raineri M.B.A.Chief Manufacturing & Technology OfficerN/AN/AN/A
Dr. Christopher MasonChief Scientific OfficerN/AN/A1959
Ms. Monique Da SilvaSr. VP of Corp. CommunicationsN/AN/AN/A
Ms. Georgette VerdinChief HR OfficerN/AN/AN/A
Ms. Deanna M. Petersen M.B.A., MBAChief Bus. OfficerN/AN/A1962
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

AVROBIO, Inc.’s ISS Governance QualityScore as of December 3, 2020 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.